InsiderTrades.com logo
Celia Eckert net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Celia Eckert Biography and Net Worth

Senior Vice President, General Counsel and Corporate Secretary of Xencor

Ms. Eckert joined Xencor as vice president, general counsel and corporate secretary in September 2019. Previously she served as vice president, corporate legal at Synthetic Genomics, Inc. In this role she negotiated licensing and financial transactions and supported other corporate legal matters. Prior to Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom, Inc., and as senior director, legal affairs at Prometheus Laboratories, Inc. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Pillsbury Winthrop Shaw Pittman LLP and at Jones Day. Ms. Eckert earned a B.A. in political science from the University of California, Los Angeles, and a J.D. from the University of California, Hastings School of Law.

What is Celia Eckert's net worth?

The estimated net worth of Celia Eckert is at least $398,728.05 as of March 11th, 2024. Ms. Eckert owns 45,465 shares of Xencor stock worth more than $398,728 as of May 13th. This net worth approximation does not reflect any other investments that Ms. Eckert may own. Additionally, Ms. Eckert receives a salary of $641,850.00 as Senior Vice President, General Counsel and Corporate Secretary at Xencor. Learn More about Celia Eckert's net worth.

How old is Celia Eckert?

Ms. Eckert is currently 51 years old. There are 4 older executives and no younger executives at Xencor. The oldest executive at Xencor is Dr. Nancy Valente M.D., Executive VP & Chief Development Officer, who is 65 years old. Learn More on Celia Eckert's age.

What is Celia Eckert's salary?

As the Senior Vice President, General Counsel and Corporate Secretary of Xencor, Inc., Ms. Eckert earns $641,850.00 per year. There are 3 executives that earn more than Ms. Eckert. The highest earning executive at Xencor is Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, President & Director, who commands a salary of $1,070,000.00 per year. Learn More on Celia Eckert's salary.

How do I contact Celia Eckert?

The corporate mailing address for Ms. Eckert and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at investors@xencor.com. Learn More on Celia Eckert's contact information.

Has Celia Eckert been buying or selling shares of Xencor?

Celia Eckert has not been actively trading shares of Xencor during the past quarter. Most recently, Celia Eckert sold 850 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.50, for a transaction totalling $19,975.00. Following the completion of the sale, the senior vice president now directly owns 45,465 shares of the company's stock, valued at $1,068,427.50. Learn More on Celia Eckert's trading history.

Who are Xencor's active insiders?

Xencor's insider roster includes Bassil Dahiyat (CEO), John Desjarlais (Executive Vice President, Research & Chief Scientific Officer), Celia Eckert (Senior Vice President, General Counsel and Corporate Secretary), Kurt Gustafson (Director), Alan Montgomery (Director), and Allen Yang (CMO). Learn More on Xencor's active insiders.

Are insiders buying or selling shares of Xencor?

In the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 176,995 shares worth more than $3,994,070.52. The most recent insider tranaction occured on May, 2nd when EVP Nancy Valente sold 4,616 shares worth more than $50,914.48. Insiders at Xencor own 4.8% of the company. Learn More about insider trades at Xencor.

Information on this page was last updated on 5/2/2025.

Celia Eckert Insider Trading History at Xencor

See Full Table

Celia Eckert Buying and Selling Activity at Xencor

This chart shows Celia Eckert's buying and selling at Xencor by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Xencor Company Overview

Xencor logo
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $8.77
Low: $8.62
High: $9.18

50 Day Range

MA: $10.63
Low: $7.67
High: $13.87

2 Week Range

Now: $8.77
Low: $7.16
High: $27.24

Volume

822,244 shs

Average Volume

639,359 shs

Market Capitalization

$624.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99